Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hemangiosarcoma × Immunoglobulin G × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 11 Lung Neoplasms 10 Fallopian Tube Neoplasms 10 Carcinoma, Non-Small-Cell Lung 7 Melanoma 6 Glioblastoma 6 Urinary Bladder Neoplasms 5 Triple Negative Breast Neoplasms 5 Colorectal Neoplasms 5 Carcinoma, Renal Cell 5 Carcinoma, Hepatocellular 5 Brain Neoplasms 4 Pancreatic Neoplasms 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma 2 Prostatic Neoplasms 2 Oligodendroglioma 2 Nasopharyngeal Carcinoma 2 Medulloblastoma 2 Gliosarcoma 2 Carcinoma, Neuroendocrine 2 Brenner Tumor 2 Adenocarcinoma of Lung 2 Vipoma 1 Uveal Melanoma 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Turcot syndrome 1

Interventions

Paclitaxel 5 Doxorubicin 5 Gemcitabine 4 pembrolizumab 3 pazopanib 3 durvalumab 3 Sorafenib 3 Docetaxel 3 trebananib 2 spartalizumab 2 brostallicin 2 Propranolol 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 Ipilimumab 2 Imatinib Mesylate 2 Carboplatin 2 Bevacizumab 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 tremelimumab 1 trastuzumab duocarmazine 1 temsirolimus 1 talazoparib 1 soblidotin 1 sintilimab 1 sarilumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04668300 2025-10-09

DOSa

M.D. Anderson Cancer Center

Phase 2 Active not recruiting

Hemangiosarcoma, Liposarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡